1. Scrip
  2. >>Business
  3. >>Deals

India M&A Uptick: Have The Planets Aligned?

 
• By Anju Ghangurde

The recent uptick in M&A on the Indian pharmaceutical market points to tempered valuations and the potential for further consolidation. Scrip spoke to a cross-section of experts including investment bankers on deal street expectations, foreign interest in M&A and whether family-led Indian firms may now be more open to sell-offs.

Big fish
INDIA HAS SEEN A SPURT IN M&A AMID TEMPERED VALUATIONS

Two pharma M&A deals on the trot in November have highlighted the softened valuation expectations by sellers on the fragmented Indian market, potentially setting the tone for more consolidation.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Novartis Doubles Down On Push For Higher Drug Prices In Europe

 
• By Jessica Merrill

CEO Vas Narasimhan urged European governments to spend more to support drug innovation during Novartis's first-quarter results call.

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

 
• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.

BridgeBio Takes A Victory Lap With First Full Quarter Of Attruby Sales

 
• By Mandy Jackson

BridgeBio reported $36.7m in Q1 2025 sales of its ATTR-CM drug Attruby, tripling consensus forecasts. Vyndaquel-maker Pfizer acknowledged the product’s impact during the quarter.